Skip to main content
Be The InvestorBe The Investor logo
S&P 500
7,690.73+0.41%
After Hours7,672.09-0.24%
Nasdaq Composite
26,430.89+1.11%
After Hours26,261.26-0.64%
Dow Jones
51,966.03-0.07%
After Hours51,963.04-0.01%
Russell 2000
2,728.30+0.25%
After Hours2,722.53-0.21%
VIX
VIX
18.83+2.11%
Bitcoin
81,248.16-0.73%
Ethereum
2,378.99-1.08%
Solana
103.90-0.98%
Gold
4,142.50-0.42%
Silver
57.32+0.07%
Copper
6.568-0.12%
WTI Crude Oil
100.68+2.17%
US 10-Year Treasury Yield
5.136+0.75%
Home›Stocks›PCVX
OverviewChartNewsFinancialsBusiness ModelCompetitorsStatisticsAnalysisEarningsValuationHoldersOptionsInsidersForecastCompareFAQ
PCVX

Vaxcyte, Inc.

PCVX
NASDAQUnited States flagUSReal-Time Price
$63.68USD
+0.06 (+0.09%)Today
$63.68+0.00 (+0.00%)Pre-Market7:42 AM ET
BTI Score
Near Future
57
Long Term
53
BTI Fair Market Cap
$3.19B
+197.47% vs fair
Biotechnology
High Risk

Vaxcyte, Inc. (PCVX) Valuation

Is Vaxcyte, Inc. (PCVX) overvalued or undervalued? BTI's fair-value estimate, DCF model and valuation multiples show the premium or discount to intrinsic worth.

Valuation Snapshot

P/E (TTM)
Trailing Price-to-Earnings
—
Forward P/E
Next 12 months estimate
—
PEG Ratio
P/E to Growth ratio
—
Price / Sales
Market cap vs. revenue
—
Price / Book
Market cap vs. book value
—
EV / EBITDA
Enterprise value multiple
—
Earnings Yield
Inverse of P/E
—
Revenue Growth
Year-over-year
—

Valuation Risk

Vaxcyte, Inc.'s valuation multiples are within a moderate range, suggesting the market is not pricing in excessive optimism. Investors should monitor growth execution relative to valuation.

Run Full Valuation Model
DCF, multiples, scenario analysis and AI fair value for PCVX